—Retrospective Cohort Study Shows Significant Reductions in All-Cause and Respiratory Disease-Related Hospitalizations in the 12 Months Following ARIKAYCE® (amikacin liposome inhalation suspension) Initiation in Real-World Settings— —Post-Hoc Analysis of Phase 2 WILLOW…
Go toTop